Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02837575 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine

A Phase 2 study, sponsored by Vical.

Completed
Registry status
Phase 2
Development phase
261
Enrollment target

NCT02837575: Completed Phase 2 study, sponsored by Vical.

NCT02837575 is a Phase 2 study that has completed, run by Vical. The registered enrollment target is 261 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02837575, a Phase 2 study, has completed, sponsored by Vical.

COMPLETED
Registry status
Phase 2
Development phase
261 participants
Enrollment target

Study Summary

The purpose of this trial is to evaluate the safety and efficacy of a therapeutic DNA vaccine in adults with symptomatic herpes simplex virus type 2 (i.e., genital herpes).

Interventions

  • BIOLOGICAL VCL-HB01
  • OTHER Phosphate-buffered saline

Trial Details

FieldValue
Enrollment Target 261 participants
Start Date 2016-09
Est. Completion 2018-12
Phase Phase 2
Vical

13 total trials

What the finished NCT02837575 record still lists

NCT02837575 is an interventional study that assigns participants to a tested intervention. The registered 261 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% higher).

The record links to 0 conditions, and to 2 interventions - of which VCL-HB01 is the first listed.

NCT02837575 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02837575 about?

NCT02837575 is a clinical study titled "Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine". The purpose of this trial is to evaluate the safety and efficacy of a therapeutic DNA vaccine in adults with symptomatic herpes simplex virus type 2 (i.e., genital herpes).

What is the current status of trial NCT02837575?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 261 participants. The study started on 2016-09. Estimated completion is 2018-12.

What interventions are being tested in trial NCT02837575?

The interventions under investigation include: VCL-HB01 (BIOLOGICAL), Phosphate-buffered saline (OTHER).

Who is sponsoring clinical trial NCT02837575?

This trial is sponsored by Vical, which has 13 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02837575's enrollment target sits among peer trials

261 210th of 2000 higher than 1,791 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05124912 · 261 participants · NA

    REMASTer: REcurrent Brain Metastases After SRS Trial

  • NCT06559891 · 261 participants · NA

    THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension

  • NCT03713268 · 262 participants

    Intraoperative OCT Guidance of Intraocular Surgery II

  • NCT06074380 · 262 participants · Phase 4

    Non Inferiority Trial Investigating Surfactants Administered Via MIST

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02837575, the US trial registry maintained by the National Library of Medicine. NCT02837575 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.